000277116 001__ 277116
000277116 005__ 20240229155010.0
000277116 0247_ $$2doi$$a10.1200/PO.23.00015
000277116 0247_ $$2pmid$$apmid:37364231
000277116 0247_ $$2altmetric$$aaltmetric:150650956
000277116 037__ $$aDKFZ-2023-01281
000277116 041__ $$aEnglish
000277116 082__ $$a610
000277116 1001_ $$0P:(DE-He78)fefb13288db2a051ee6a10615da0b719$$aHeipertz, Anna-Elisa$$b0$$eFirst author$$udkfz
000277116 245__ $$aOutcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.
000277116 260__ $$aAlexandria, VA$$bAmerican Society of Clinical Oncology$$c2023
000277116 3367_ $$2DRIVER$$aarticle
000277116 3367_ $$2DataCite$$aOutput Types/Journal article
000277116 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687860106_19594
000277116 3367_ $$2BibTeX$$aARTICLE
000277116 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277116 3367_ $$00$$2EndNote$$aJournal Article
000277116 500__ $$a#EA:B310#LA:B310#
000277116 520__ $$aINFORM is an international pediatric precision oncology registry, prospectively collecting molecular and clinical data of children with recurrent, progressive, or very high-risk malignancies. We have previously identified a subgroup of patients with improved outcomes on the basis of molecular profiling. The present analysis systematically investigates progression-free survival (PFS) and overall survival (OS) of patients receiving matching targeted treatment (MTT) with the most frequently applied drug classes and its correlation with underlying molecular alterations.A cohort of 519 patients with relapsed or refractory high-risk malignancies who had completed a follow-up of at least 2 years or shorter in the case of death or loss to follow-up was analyzed. Survival times were compared using the log-rank test.MTT with anaplastic lymphoma kinase (ALK), neurotrophic tyrosine receptor kinase (NTRK), and B-RAF kinase (BRAF) inhibitors showed significantly improved PFS (P = .012) and OS (P = .036) in comparison with conventional treatment or no treatment. However, analysis of the four most commonly applied MTT groups, mitogen-activated protein kinase (MEK- n = 19), cyclin-dependent kinase (CDK- n = 23), other kinase (n = 62), and mammalian-target of rapamycin (mTOR- n = 20) inhibitors, did not reveal differences in PFS or OS compared with conventional treatment or no treatment in patients with similar molecular pathway alterations. We did not observe differences in the type of pathway alterations (eg, copy number alterations, single-nucleotide variants, InDels, gene fusions) addressed by MTT.Patients with respective molecular alterations benefit from treatment with ALK, NTRK, and BRAF inhibitors as previously described. No survival benefit was observed with MTT for mutations in the MEK, CDK, other kinase, or mTOR signaling pathways. The noninterventional character of a registry has to be taken into account when interpreting these data and underlines the need for innovative interventional biomarker-driven clinical trials in pediatric oncology.
000277116 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000277116 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277116 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b1$$udkfz
000277116 7001_ $$0P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aPfaff, Elke$$b2$$udkfz
000277116 7001_ $$0P:(DE-He78)2f592d9d8339bee07cca3956b7472b61$$aSchramm, Kathrin$$b3$$udkfz
000277116 7001_ $$0P:(DE-He78)261d2b84aded878003e6e35d18113831$$aBlattner-Johnson, Mirjam$$b4$$udkfz
000277116 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b5$$udkfz
000277116 7001_ $$0P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4$$aJones, Barbara$$b6$$udkfz
000277116 7001_ $$0P:(DE-He78)916e1165f772de17b13675a244307e95$$aZuliani, Cecilia$$b7$$udkfz
000277116 7001_ $$00000-0003-2059-4814$$aHutter, Caroline$$b8
000277116 7001_ $$00000-0001-9195-0797$$aLohi, Olli$$b9
000277116 7001_ $$00000-0002-5178-0655$$aKattamis, Antonis$$b10
000277116 7001_ $$aDachowska-Kalwak, Iwona$$b11
000277116 7001_ $$00000-0001-5885-7101$$aNilsson, Anna$$b12
000277116 7001_ $$aGerber, Nicolas U$$b13
000277116 7001_ $$00000-0002-6780-0585$$aLangenberg, Karin P S$$b14
000277116 7001_ $$00000-0003-4030-3228$$aGoemans, Bianca$$b15
000277116 7001_ $$00000-0001-6892-8268$$aZwaan, C Michel$$b16
000277116 7001_ $$aMolenaar, Jan J$$b17
000277116 7001_ $$0P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aJäger, Natalie$$b18$$udkfz
000277116 7001_ $$00000-0002-5435-7860$$aDirksen, Uta$$b19
000277116 7001_ $$0P:(DE-He78)4ad08e18c452a1684b5437a2f9a1052a$$aWitt, Ruth$$b20$$udkfz
000277116 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b21$$udkfz
000277116 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b22$$udkfz
000277116 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b23$$udkfz
000277116 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b24$$udkfz
000277116 7001_ $$0P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$avan Tilburg, Cornelis Martinus$$b25$$eLast author$$udkfz
000277116 773__ $$0PERI:(DE-600)2964799-X$$a10.1200/PO.23.00015$$gVol. 7, no. 7, p. e2300015$$n7$$pe2300015$$tJCO precision oncology$$v7$$x2473-4284$$y2023
000277116 909CO $$ooai:inrepo02.dkfz.de:277116$$pVDB
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fefb13288db2a051ee6a10615da0b719$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2f592d9d8339bee07cca3956b7472b61$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)261d2b84aded878003e6e35d18113831$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)916e1165f772de17b13675a244307e95$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-5435-7860$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4ad08e18c452a1684b5437a2f9a1052a$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000277116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$aDeutsches Krebsforschungszentrum$$b25$$kDKFZ
000277116 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000277116 9141_ $$y2023
000277116 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-22
000277116 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-22
000277116 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJCO PRECIS ONCOL : 2022$$d2023-10-27
000277116 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000277116 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000277116 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000277116 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-27
000277116 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-27
000277116 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000277116 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000277116 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-27
000277116 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-27
000277116 9202_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000277116 9200_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000277116 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000277116 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000277116 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x2
000277116 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatische Gliomforschung$$x3
000277116 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x4
000277116 980__ $$ajournal
000277116 980__ $$aVDB
000277116 980__ $$aI:(DE-He78)B310-20160331
000277116 980__ $$aI:(DE-He78)HD01-20160331
000277116 980__ $$aI:(DE-He78)B062-20160331
000277116 980__ $$aI:(DE-He78)B360-20160331
000277116 980__ $$aI:(DE-He78)C060-20160331
000277116 980__ $$aUNRESTRICTED